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Abstract
Introduction: While adalimumab is licensed for ankylosing spondylitis (AS), open uncontrolled studies suggest
therapeutic efficacy of TNF-inhibitors in juvenile onset AS (JoAS).
Methods: A total of 32 patients aged 12 to 17 years with severe, active and refractory JoAS were enrolled in a
multicenter, randomized, double-blind, placebo-controlled parallel study of 12 weeks, followed by open-label
adalimumab until week 24 for all patients. ASAS40 was used as the primary, and ASAS20, PedACR and single items
were used as the secondary outcome measures for the intention to treat population.
Results: A total of 17 patients were randomized to receive adalimumab 40 mg/2 weeks and 15 patients received
placebo. Two patients (one of each group) discontinued prematurely due to insufficient efficacy and were labeled
as non-responders. In the double-blind part, more patients on adalimumab achieved an ASAS40 at week 4 (41%),
week 8 (53%) and week 12 (53%) than on placebo (20%, 33%, 33%), while differences at week 8 only reached
borderline significance (P = 0.05). Also, at 4, 8 and 12 weeks ASAS20/PedACR30/70 response rates were higher in
the adalimumab group (53%/53%/29%; 59%/76%/41%; 53%/65%/53%) compared to placebo (27%/27%/7%; 27%/
33%/13%; 33%/40%/27%). In the adalimumab group a significant decrease of all disease activity parameters was
noted at week 12 and was even more pronounced at week 24. At week 12 the Bath Ankylosing Spondylitis
Disease activity spinal inflammation score decreased by 65% (P <0.001), the back pain score decreased by 50%
(P <0.005), the Bath AS Functional Index (BASFI) score decreased by 47% (P <0.02), while the Childhood Health
Assessment Questionnaire-Disability Index (CHAQ-DI) score improved by 65% (P <0.005). ANCOVA analysis
demonstrated superiority of adalimumab over placebo for the physician global assessment of disease activity,
parents’ global assessment of subject’s overall well-being, active joint count (all P <0.05) and erythrocyte
sedimentation rate (ESR) (P <0.01).
During the 12-week controlled phase, 29 AEs occurred in 10 patients on placebo compared to 27 AEs in 11 patients
on adalimumab. Injection site reactions were the most common adverse events. There were 17 various infections
occurring in the double-blind phase, 8 on placebo, 9 on adalimumab and a further 19 in the open label period.
Conclusions: Adalimumab was well tolerated and highly effective in a double-blind randomized trial in patients
with JoAS. Treatment effects rapidly occurred and persisted for at least 24 weeks of treatment.
Trial registration: EudraCT 2007-003358-27.
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Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease that affects 0.2 to 0.8% of the population
[1]. Although AS typically presents in the early 20s, it can
present in childhood. In juvenile onset AS (JoAS), manifes-
tations start in individuals <16 years of age and progress to
sacroiliitis and spine involvement later on. Among patients
with AS, prevalence rates for juvenile-onset vary from
9% to 21% in white populations [2].
Juvenile- and adult-onset spondyloarthropathies, parti-
cularly AS, differ in several aspects. Most differences con-
sist of symptoms at the onset [3-7]. Adults are more likely
to present with axial manifestations. In contrast to adults,
children and adolescents with JoAS have peripheral arthri-
tis and enthesitis in the initial years and axial symptoms
5 to 10 years later. The severity of AS is greater in juve-
niles than in adults since more juveniles require hip repla-
cements, are in functional classes III and IV, and exhibit
higher mean Bath AS Functional Index (BASFI) scores.
Differences in functional outcome have also been
reported that depend on the age of onset. In a study com-
paring 24 JoAS with 71 adult AS patients, JoAS had
worse functional outcome [8]. Early-course JoAS is often
remitting. The number of peripheral joints involved
remains limited with hips, knees, ankles and feet affected.
Persistent peripheral joint involvement may be more
frequent in JoAS than in adult AS and, particularly coxi-
tis, may lead to a worse outcome.
JoAS describes a disease of childhood and adolescents
which is not incorporated in juvenile idiopathic arthritis
(JIA) [9]. The enthesitis and arthritis category of the juve-
nile idiopathic arthritis covers patients with exclusively
peripheral joint involvement and those with additional
axial involvement [10]. Therefore, most of the patients
with JoAS will probably fulfill the diagnosis of the enthe-
sitis and arthritis category of the JIA classification [10].
So far, treatment options are limited for JoAS. Nonster-
oidal anti-inflammatory agents (NSAIDs) are the mainstay
of treatment providing symptomatic relief. Disease modi-
fying drugs (DMARDs) like methotrexate and other
immunosuppressants have not shown to be useful for
treatment of JoAS. Systemic and intra-articular corticos-
teroids promote susceptibility to infections, osteoporosis
and growth disturbance.
There is now accumulating evidence that anti-TNF ther-
apy is highly effective in adult AS [11-13]. There are five
tumor necrosis factor alpha (TNFa)-blockers currently
available: adalimumab, certolizumab, etanercept, golimu-
mab and infliximab. Adalimumab is the first fully human
monoclonal antibody engineered by gene technology that
uses site-directed mutagenesis to enhance its binding effi-
ciency to TNF. It does not contain non-human or artificial
protein sequences [14]. Adalimumab binds only to TNFa
[15] and has a half-life of approximately two weeks [16].
The antibody has been extensively studied in vitro as well
as in vivo and is non-toxic in animal toxicology studies.
Adalimumab has been studied for treatment of active
resistant polyarticular JIA [17]. Severe adverse events have
remained rare but infections, including tuberculosis, have
been reported [18-20]. Currently, the benefits of anti-TNF
therapy seem to outweigh these shortcomings.
The first evidence of therapeutic efficacy of TNF-inhibi-
tors in patients with juvenile spondylarthopathies, including
JoAS, was published years ago as case series or open studies
[21-24].
Adalimumab so far has not been studied in JoAS
patients but has been in adult AS. Those studies resulted
in the approval of TNF inhibitors for adult AS, while in
children and adolescents, TNF inhibitors are licensed only
for polyarticular juvenile rheumatoid arthritis/juvenile
idiopathic arthritis as well as inflammatory bowel disease
[25-29].
In view of these results, we chose to study adalimumab
in children with JoAS. For this study, only those patients
were selected who had active axial involvement of JoAS
with both clinical (limitation of movement of axial pain)
and magnetic resonance imaging (MRI) evidence.
Materials and methods
Patients
In the absence of validated diagnostic criteria for JoAS,
diagnosis of JoAS in this study required the following
two conditions (I) bilateral active sacroiliitis confirmed
by magnetic resonance imaging OR unilateral active
sacroiliitis confirmed by magnetic resonance imaging and
active peripheral joint disease restricted to the lower
extremities (hip, knee, ankle) AND (II) at least one of
three clinical criteria: (A) limitation of lumbar spine
motion in all three planes, (B) pain or history of pain at
the dorsolumbar junction of the spine and/or (C) limita-
tion of chest expansion to 2.5 cm or less at the level of
the fourth intercostal space.
Patients included were at least 12 and up to 17 years of
age with a weight of at least 30 kg. Manifestations were
refractory to two different non-steroidal anti-inflamma-
tory drugs given at appropriate dosage and for a total of
four weeks.
Active disease was defined by a spinal inflammation
score of at least three (see below) AND at least two of
the following criteria: (1) back pain score of at least 3; (2)
patient global assessment of disease activity of at least 3;
(3) physical function score as determined by the BASFI
of at least 3.
Patients had to have stable doses of NSAIDs. Low
doses of corticosteroids of no more than 0.2 mg of pre-
dnisone per kilogram body weight per day, with a maxi-
mum of 10 mg per day, were allowed. Intra-articular and
soft-tissue corticosteroid injections were not permitted
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for four weeks prior to the Screening Visit. Patients trea-
ted with etanercept or infliximab or adalimumab or
anakinra at any time for any period or with antimalarials,
gold salts, sulfsalazine, azathioprine, penicillamine, leflu-
nomide, cyclosporine A, intravenous immunoglobulin or
methotrexate within four weeks prior to the first admin-
istration of study medication, or with plans to begin the
intake of these drugs were excluded. Additional major
exclusion criteria were a history of any chronic disease
other than JoAS, JRA/JIA, especially chronic renal dis-
ease, liver disease, hematological, gastrointestinal, pul-
monary, cardiological or neurological disease, which in
the opinion of the investigator might influence the
efficacy or safety of the study medication or which in the
opinion of the investigator might lead to an unacceptable
risk for the patient.
Study medication and dosage
On the basis of pharmacokinetic considerations and
recent experience with dosing of adalimumab in children,
a dose of 40 mg every other week was given. The study
drug was provided as an injection solution in prefilled
syringes containing 0.8 ml of placebo or adalimumab
50 mg/ml concentration. Stable doses of NSAIDs and
low dose of corticosteroids (≤10 mg per day) were per-
mitted throughout the study period.
Study design
This was a multi-center, randomized, double-blind, paral-
lel-group Phase III study. Patients with JoAS received
1:1 40 mg of adalimumab or placebo subcutaneously every
other week for a 12-week period (Controlled Phase). Clini-
cal assessments were carried out at baseline and after 4, 8
and 12 weeks. At week 12 all patients who finalized the
12-week double-blind study received adalimumab. Further
study visits occurred after 16, 20 and 24 weeks.
Adverse events
Clinical and laboratory evidence of adverse events on a
routine basis were completed throughout the study. The
investigator assessed and recorded any adverse event in
detail on the adverse event form, including the date and
time of onset, description, severity, time course, duration
and outcome, relationship of the adverse event to study
drug and alternative etiology for events not considered
‘probably related’ to study drug.
Efficacy evaluations
The clinical response to adalimumab was assessed using
the Assessment of SpondyloArthritis International
Society (ASAS) [30,31], the pediatric ACR (PedACR)
criteria [32], the Bath Ankylosing Spondylitis Disease
activity score (BASDAI) and the Bath Ankylosing Spon-
dylitis Functional Index (BASFI) [33]. The individual
domains contributing to the ASAS are (i) the spinal
inflammation, defined as mean of items 5 (overall level of
morning stiffness) and 6 (duration of morning stiffness)
of the BASDAI; (ii) back pain, defined as mean of total
back pain and nocturnal back pain; (iii) patient’s global
assessment; and (iiii) the physical function, defined as
BASFI. The categories contributing to the PedACR 30
Score are the physician’s global assessment of subject’s
disease activity (numeric rating scale, NRS), the parents’
global assessment of subject’s overall well-being (NRS),
number of active joints (swelling not due to deformity or
in joints without swelling, limitation of motion (LOM)
plus pain and/or tenderness), number of joints with
LOM, Childhood Health Assessment Questionnaire
(CHAQ) and C-reactive protein (CRP). In addition, the
erythrocyte sedimentation rate (ESR) was recorded.
The primary endpoint was the achievement of ASAS40
at week 12. A responder has been defined as a patient
who achieved improvement in at least three of four
domains contributing to the ASAS, with no worsening in
the remaining domain. An improvement of a single
domain is defined as a decrease of ≥40% and ≥2 points
on the rating scale ranging from 0 to 10. Worsening of a
single domain is defined as increase of >20% or >1 point
on the rating scale.
The PedACR30 and the PedACR70 scores were calcu-
lated as published [32].
Statistical analysis
The efficacy analyses were performed in the intention-to-
treat (ITT) population. The ITT population was defined
as all subjects who were randomized and who have
received at least one dose of the drug and at least one
post-dose efficacy assessment at any dose. Further, to
address the possible impact of major protocol violations,
an additional ‘per-protocol’ population was defined
excluding all subjects with premature discontinuation or
major protocol violations. No substantial differences
were observed between the ITT and the per protocol
analysis populations. Therefore, the ITT analysis was
chosen. Data on patients who prematurely discontinued
were included in a last observation carried forward
modus. The efficacy variables were analyzed either using
Pearson’s c2 test, U-test, independent t-tests, analysis of
covariance (ANCOVA) for repeated measures.
Independent ethical committee
The study was conducted in accordance with the protocol
ICH GCP, FDA regulations governing clinical study con-
duct, ethical principles that have their origin in the
Declaration of Helsinki, 1996 revision and 2000 revision
with subsequent clarifications, and all applicable local reg-
ulations. Before the study was initiated, the study protocol,
the Informed Consent Form and Subject Information
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were submitted to the responsible independent ethics
committee of the Aerztekammer Nordrhein, Duesseldorf,
Germany for review and it was approved on 02 May 2008.
Parents/legal guardian signed the Informed Consent form
before any study-related procedures occurred.
Results
Patient population
The target population of 50 patients could not be reached
and recruiting was stopped prematurely because of the
expiration date of the study drug. Seventeen patients were
randomized to receive adalimumab 40 mg/2 wks and
15 patients received placebo. Two patients (one of each
group) discontinued prematurely due to lack of efficacy
and were labeled as non-responders (Figure 1). Sixteen
patients of the adalimumab group and 14 patients of the
placebo group remained in the study and reached week
12, the final end point of the controlled part of the study.
All these 30 patients entered into the open labeled phase
at week 12 and remained in the study till week 24. One
patient in the adalimumab group has been diagnosed with
Complex Pain Syndrome and turned out to be an ASAS
non-responder in both phase 1 and phase 2 of the study.
The detailed baseline patients’ characteristics are out-
lined in Table 1. The median duration of specific com-
plaints was 34.9 months, the median duration since
diagnosis was 6.5 months. HLA-B27 was present in 76%
of cases. AS in the family was known in 37.5% of patients.
Two to six (median 2.5) different previous AS medica-
tions were reported; these were, predominantly, conven-
tional NSAIDs (100.0%), COX-2-inhibitoirs (28.1%), oral
corticosteroids (40.6%), intra-articular corticosteroids
(37.5%), sulfasalazine (34.4%), methotrexate (31.3%) and
COX-2-inhibitors (28.1%). Comparability of study groups
was analyzed thoroughly at baseline. A higher proportion
of patients of the placebo cohort had received oral corti-
costeroids (U-test, P = 0.04).
Efficacy results
In the double-blind part of the study, more patients on
adalimumab achieved an ASAS40, the primary outcome
parameter, at week 4 (41%), week 8 (53%) and week
12 (53%) than on placebo (20%, 33%, 33%), while differ-
ences at week 8 only reached the border significance (P =
0.05). Secondary outcome parameter, ASAS20 and Ped-
ACR30 and -70 response rates at 4, 8 and 12 weeks were
higher in the adalimumab group (Table 2).
In the adalimumab group at week 12, a decrease of all
single disease activity parameters was noted compared to
baseline. The mean (+/-SD) BASDAI spinal inflammation
score decreased from 4.3 ± 2.1 to 1.5 ± 1.7 (-66%; P <
0.001), the back pain score decreased from 5.5 ± 1.6 to
2.8 ± 2.9, (-48%; P <0.005), the BASFI score decreased from
3.8 ± 1.8 to 2.0 ± 2.3 (-47%; P <0.02), the CHAQ-DI score
improved from 1.0 ± 0.4 to 0.6 ± 0.7 (-65%; P <0.005), the
ESR improved from 23 +/- 27 mm/h to 6 +/- 3 mm/h
(- 75%; P <0.05) and finally the CRP improved from 13 +/-
22 mg/l to 4 +/- 0.8 mg/l (- 80%; P = 0.07).
In the placebo group as well, some disease activity
parameters improved while only the back pain score
decreased significantly from 6.2 ± 1.4 to 4.3 ± 2.4 (-31%;
P <0.02). In the placebo group the mean (+/- SD) BAS-
DAI spinal inflammation score decreased from 5.0 ± 2.2
to 3.8 ± 3.0 (-25%; n.s.), the BASFI score decreased from
4.2 ± 2.3 to 3.3 ± 2.6 (-20%; n.s.), the Childhood Health
Assessment Questionnaire-Disability Index (CHAQ-DI)
score improved from 1.1 ± 0.8 to 0.8 ± 0.6 (-31%; n.s.),
the ESR increased from 16 +/- 16 mm/h to 18 +/-
20 mm/h (+ 7%, n.s.) and finally the CRP increased from
5.4 +/- 9.6 mg/l to 10 +/- 26 mg/l (+ 88%) at week 12.
Improvement of the median of the individual disease
activity parameters composing the ASAS score is given in
Figure 2. The reduction of the “Spinal inflammation
Score”, the “Pain Score”, the “Physical function score”
(BASFI) and the “Patient’s Global Disease Activity Score”
was more pronounced in patients of the adalimumab
group than the placebo group, but did not reach signifi-
cance in the intergroup comparison.
Improvement of the individual disease activity para-
meters composing the PedACR Score is given in Figure 3.
Figure 1 Patient disposition. Flow chart showing the disposition
of the study patients from initial screening through week 24. All
patients screened have been randomized. One patient each in both
groups discontinued prematurely (before week 4) due to lack of
efficacy. All patients reaching week 12 of the placebo controlled
phase of the study have been admitted to the open label phase.
There were no further drop outs.
Horneff et al. Arthritis Research & Therapy 2012, 14:R230
http://arthritis-research.com/content/14/5/R230
Page 4 of 12
In patients of the adalimumab group, a marked reduction
of the median of the “Physician’s Global Disease Activity
Score”, the “Parent’s Global Assessment of subject’s overall
well-being”, the “Active Joint Count”, the “Physical Func-
tion Score” (CHAQ), the “LOM Joint Count” and the CRP
are evident, while there was no change in patients of the
placebo group for “parent’s global” and “active joint
count”, a weak decrease only for “physician’s global”,
“CHAQ” and “limited motion joint count” or an increase
for the CRP level.
Although a randomization has been performed, there
were some differences between the patient groups at base-
line (Table 1). Therefore, for statistical comparison, base-
line adjustment has been performed (Table 3). The course
of all single items was analyzed at different time points
and in the repeated measurement design to assess change
over time in the ITT population. The global treatment
difference is outlined in Table 3. The difference for physi-
cian’s global assessment of subject’s disease activity after 8
weeks (P = 0.014) and 12 weeks (P = 0.043) were statisti-
cally significant, while the tests after 4 weeks (P = 0.067)
showed marked tendencies in favor of adalimumab. The
course of parents’ global assessment of patient’s overall
well-being showed significant differences (week 4: P =
0.022, week 8: P = 0.045, week 12: P = 0.013) in the entire
course of double-blind treatment phase. The course of the
number of active joints showed significant advantages of
adalimumab at week 8 (P = 0.002).
The course of CHAQ showed nearly significant differ-
ences in favor of adalimumab at week 8 (P = 0.054).
In the open label phase of the study, all patients received
active treatment with adalimumab. The improvements





Age (years; Mean +/-SD) 15.1 +/- 1.5 15.5 +/- 1.7
Gender female (%) 7 (41%) 8 (53%)
Duration since diagnosis (years; Mean +/- SD) 0.9 +/- 1.1 2.5 +/- 2.8
Duration since first symptoms (years; Mean +/-SD) 2.3 +/- 1.5 4.0 +/- 3.1
Family history with ankylosing spondylitis 6 (35.3%) 6 (40.0%)
HLA B27 positive 10/14 (71.4%) 9/11 (81.8%)
Previous treatment courses
Conventional NSAIDs 17 (100%) 15 (100%)







Methotrexate 4 (23.5) 6 (40)
Sulfasalazine 4 (23.5) 7 (46.7)
Concomitant medication
Conventional NSAIDs 14 (82.4%) 14 (93.3%)
Coxibes 1 (5.9%)
Corticosteroids, oral 3 (17.6%) 5 (33.3%)
No. of active joints mean (SD) 3.8 (2.6) 4.9 (5.1)
No. of joints with LOM mean (SD) 2.2 (2.6) 4.7 (5.9)
BASDAI Spinal inflammation mean (SD) 4.29 (1.97) 5.24 (2.34)
BASDAI Total score mean (SD) 4.75 (1.30) 5.45 (1.50)
Back pain at any time mean (SD) 6.0 (1.4) 7.2 (1.6)*
Back pain at night mean (SD) 5.3 (2.4) 4.9 (2.6)
Pain score mean (SD) 5.65 (1.58) 6.07 (1.46)
Patient’s Global NRS mean (SD) 5.94 (1.85) 6.87 (1.88)
Physical function (BASFI) mean (SD) 3.85 (1.80) 4.17 (2.31)
Physical function (CHAQ) mean (SD) 0.993 (0.420) 0.958 (0.397)
Physician’s Global NRS mean (SD) 5.59 (1.77) 6.07 (2.19)
Parent’s Global NRS mean (SD) 5.94 (1.39) 6.07 (2.19)
Back pain at any time mean (SD) 6.0 (1.4) 5.60 (2.06)
#A higher proportion of patients of the placebo cohort had received oral corticosteroids (U-test, P = 0.04). *Back pain at any time was the only significantly
different clinical item between both treatment groups.
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Table 2 Efficacy: primary and secondary endpoints
Endpoint Number (%) Odd’s ratio (95% CI) P-value*
Adalimumab (n = 17) Placebo (n = 15)
Primary endpoint
ASAS40 week 4 7 (41) 3 (20) 2.3 (0.6 to 13.8) 0.20
week 8 9 (53) 3 (20) 3.6 (0.9 to 21.9)* 0.05
week 12 9 (53) 5 (33) 1.6 (0.5 to 9.5) 0.26
Secondary endpoint
ASAS20 week 4 9 (53) 10 (59) 4 (27) 4 (27)
week 8 2.4 (0.7 to 13.7) 3.0 (0.9 to 17.6) 0.13 0.07
week 12 9 (53) 5 (33) 1.6 (0.5 to 9.5) 0.26
PedACR30 week 4 9 (53) 4 (27) 2.4 (0.7 to 13.7) 0.13
week 8 13 (76) 5 (33) 5.1 (1.4 to 30.7) 0.01
week 12 11 (65) 6 (40) 2.0 (0.7 to 11.5) 0.16
PedACR70 week 4 5 (29) 1 (6.7) 6.8 (0.6 to 57.1) 0.10
week 8 7 (41) 2 (13) 4.1 (0.8 to 26.8) 0.08
week 12 9 (53) 4 (27) 2.4 (0.7 to 13.7) 0.13
In this intention to treat analysis one patient of each group who discontinued prematurely was labeled as non-responder. * Chi square test.
Figure 2 Reduction of the Items contributing to the ASAS-Score during 12 weeks of blinded treatment. (A) Spinal inflammation Score, (B) Pain
Score, (C) Physical function (Bath ankylosing spondylitis functional index), (D) Patient’s Global Assessment of disease activity. The median is given.
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obtained in the adalimumab group were maintained or
even augmented in the open-label follow-up study phase
in those patients of the sequence adalimumab - adalimu-
mab (Figure 4A-D). Due to the improvement reached in
the patients treated by the sequence placebo-adalimumab
in the open label study phase, the treatment differences
observed after 12 weeks between placebo and adalimumab
showed decreasing tendencies. After 24 weeks, there were
no or only slight differences in favor of the long-term
treatment with adalimumab.
Safety results
In the double-blind study phase 27 adverse events were
observed in 10 of 17 patients on adalimumab (58.8%) and
29 adverse events were observed in 10 of 15 patients on
placebo (66.7%), predominantly as ‘Infections and infesta-
tions’ (adalimumab: N = 6; placebo: N = 6) and ‘General
disorders and administration site conditions’ (adalimumab
N = 3; placebo: N = 4). Adverse events at least possibly
related to the study medication (adverse drug reactions)
were reported in four patients on adalimumab (23.6%) and
five patients on placebo (33.3%), predominantly as ‘Gen-
eral disorders and administration site conditions’ (adali-
mumab: N = 3; placebo: N = 3). Drug related infections
were reported only once on adalimumab (appendicitis).
In the open study phase, there were 19 adverse events
in 10 of 16 patients of the sequence adalimumab-adali-
mumab (62.5%) and 29 adverse events in 7 of 14 patients
in the sequence placebo-adalimumab (50.0%). The most
common events were ‘Infections and infestations’ (adali-
mumab-adalimumab: N = 8; placebo-adalimumab: N =
6). Deviating from the double-blind study phase, the
infections were predominantly classified by the local
investigators as related to the study medication (N = 9),
Figure 3 Clinical improvement of the Items contributing to the PedACR during 12 weeks of blinded treatment. (A) Physician’s Global
Assessment of disease activitry, (B) Parent’s Global Assessment of overall well being, (C) Numbers of joints with active arthritis, (D) Childhood
Health Assessment Questionnaire Disability Index, (E) joints with limited range of motion and serum levels of C-reactive Protein. The median is
given. The global treatment difference was significant for physician’s global assessment (P = 0.021), parents’ global assessment (P = 0.016). At
week 8 significant differences were noted for physician’s global assessment (P = 0.006), parents’ global assessment (P = 0.025), the number of
active joints (P = 0.0007), the CHAQ-DI (P = 0.017).
Horneff et al. Arthritis Research & Therapy 2012, 14:R230
http://arthritis-research.com/content/14/5/R230
Page 7 of 12
while ‘General disorders and administration site condi-
tions’ occurred in only N = 3 patients.
Serious adverse events occurred in three patients dur-
ing the double-blind study phase, two on adalimumab
(appendicitis, tendonitis) and one on placebo (gastritis)
and in four patients during the open study phase upon
adalimumab, two in the sequence adalimumab-adalimu-
mab (vertigo, general pain) and two in the sequence
placebo-adalimumab (colitis, pyelonephritis). In two
patients the events (appendicitis and pyelonephritis)
were possibly related to adalimumab, the further serious
adverse events were not related or probably not related,
respectively, to the study medication (Table 4). No clini-
cally significant laboratory abnormalities were related to
the treatment with adalimumab. In all, the tolerability
of the study medication was assessed very good or good
in the majority of patients (patient’s overall assessment:
27/32 (84.4%), investigator’s overall assessment: 30/32
(93.8%)).
Discussion
This randomized, double-blind trial showed the clinical
efficacy of the TNF inhibitor adalimumab in patients
with JoAS. Treatment with adalimumab for 12 weeks was
associated with a reduction in disease activity as assessed
by a number of clinical end points, biochemical markers
of disease, and quality of life. These data show that TNF
antagonism is a valid approach to the short term treat-
ment of juvenile ankylosing spondylitis.
Improvement occurred rapidly, mostly within four to
eight weeks. The strength of improvement, furthermore,
increased from week 12 to week 24 in those patients
already treated with adalimumab in phase 1 of the study.
Patients receiving placebo in phase 1 of the study also
Table 3 Comparison of PedACR and ASAS domains after baseline adjustment
Week 4 Week 8 Week 12 Treatment
P-value*
Physicians’ Global Adalimumab 2.97 +/- 0,53 2.44 +/- 0.53 2.67 +/- 0.54
5.81# Placebo 4.43 +/- 0.57 4.43 +/- 0.57 4.31 +/- 0.57
Difference (95% confidence Interval) -1.47 +/- 0.78 -2.00 +/- 0.78 -1.64 +/- 0.79 0.021
Parents’ Global Adalimumab 3.45 +/- 0.62 2.86 +/- 0.62 2.85 +/- 0.63
5.78 Placebo 5.62 +/- 0.66 4.75 +/- 0.66 5.24 +/- 0.67
Difference (95% confidence Interval) -2.17 +/- 0.91 -1.89 +/- 0.91 -2.39 +/- 0.93 0.014
No. Active Joints Adalimumab 1.72 +/- 0.49 1.31 +/- 0.49 1.99 +/- 0.5
4.31 Placebo 2.59 +/- 0.52 3.65 +/- 0.52 2.83 +/- 0.53
Difference (95% confidence Interval) -0.87 +/- 0.72 -2.35 +/- 0.72 -0.84 +/- 0.73 0.032
No. LOM Joints Adalimumab 1.60 +/- 0.47 1.78 +/- 0.47 1.84 +/- 0.48
3.34 Placebo 2.38 +/- 0.50 2.65 +/- 0.50 2.01 +/- 0.52
Difference (95% confidence Interval) -0.78 +/- 0.69 -0.87 +/- 0.69 -0.17 +/- 0.71 0.198
CHAQ Adalimumab 0.57 +/- 0.12 0.42 +/- 0.12 0.44 +/- 0.12
0.98 Placebo 0.80 +/- 0.12 0.75 +/- 0,12 0.74 +/- 0.13
Difference (95% confidence Interval) -0.22 +/- 0.17 -0.34 +/- 0.17 -0.30 +/- 0.17 0.079
CRP Adalimumab 0.99 +/- 2.77 3.92 +/- 2.77 1.98 +/- 2.89
10.34 Placebo 5.91 +/- 3.05 8.69 +/- 3.05 9.72 +/- 3.05
Difference (95% confidence Interval) -4.92 +/- 4.14 -4.76 +/- 4.14 -7.74 +/- 4.23 0.103
Spinal inflammation Adalimumab 2.60 +/- 0.56 2.64 +/- 0.56 2.05 +/- 0.56
4.73 Placebo 3.56 +/- 0.60 3.51 +/- 0.60 3.50 +/- 0.60
Difference (95% confidence Interval) -0.97 +/- 0.83 -0.87 +/- 0.83 -1.45 +/- 0.83 0.179
Pain Score Adalimumab 3.60 +/- 0.59 3.60 +/- 0.59 3.23 +/- 0.60
5.84 Placebo 4.38 +/- 0.63 3.98 +/- 0.63 4.33 +/- 0.64
Difference (95% confidence Interval) -0.78 +/- 0.87 -0.38 +/- 0.87 -1.11 +/- 0.88 0.360
Patients’ Global Adalimumab 4.50 +/- 0.54 3.97 +/- 0.54 3.76 +/- 0.55
6.38 Placebo 5.44 +/- 0.58 4.70 +/- 0.58 4.82 +/- 0.59
Difference (95% confidence Interval) -0.94 +/- 0.80 -0.74 +/- 0.80 -1.06 +/- 0.81 0.210
BASFI Adalimumab 2.53 +/- 0.47 2.38 +/- 0.47 2.14 +/- 0.48
4.00 Placebo 3.36 +/- 0.50 3.28 +/- 0.50 3.09 +/- 0.51
Difference (95% confidence Interval) -0.84 +/- 0.69 -0.90 +/- 0.69 -0.95 +/- 0.70 0.171
*Total treatment difference, repeated measurement design. # Baseline adjusted value. $ ANCOVA analysis.
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demonstrated marked improvement in phase 2 after they
were switched from placebo to adalimumab.
The comparison of the defined primary objective
ASAS40 at 12 weeks failed to demonstrate statistically
significant superiority. Due to the impressive differences
outlined in Tables 2 and 3 and in Figures 2, 3 and 4, this
failure is most likely due to the small sample sizes. Unfor-
tunately, recruitment had to be stopped before the target
population of 50 patients could be reached. Furthermore,
two patients (one of each group) discontinued prema-
turely and assessment of the efficacy of a 12 weeks trial
of the study drug, therefore, was impossible. One patient
turned out to be classified with pain amplification syn-
drome and failed to meet the improvement criteria.
Reiff et al. presented a small open study using etanercept
for treatment of JoAS [34]. Eight patients (seven males),
with a mean age of 15.9 years (range 12 to 25 years)
suffering from juvenile ankylosing spondylitis for a mean
of 4.5years (range 1.2 to 17.5 years) were included. Six
patients were HLA-B27 positive. Treatment has been per-
formed with etanercept at an average dosage of 0.4 mg/kg
body weight, which is the dosage recommended for treat-
ment of polyarticular JIA [25]. The therapeutic effects
were evident for up to more than 24 months. In another
open study on 10 patients with juvenile spondylarthritis,
improvement with anti-TNFa therapy has been demon-
strated using either infliximab (n = 8) or etanercept
(n = 2). [35].
A 12-week, randomized, double-blind, placebo-con-
trolled trial using infliximab showing efficacy and safety
of TNF-inhibition in juvenile-onset spondyloarthritis trial
was presented as abstract only [36]. In this study, the
American College of Rheumatology pediatric core criteria
definition of improvement in juvenile arthritis, which
currently have not been validated for juvenile spondylar-
thropathies, have been used only. Dramatic improvement
could be shown in this study. In our controlled trial, in
addition to the ACR criteria, we also applied the ASAS
Working Group response criteria ASAS20 and ASAS40,
although they have not so far been validated for juvenile
AS. Improvements were shown with both sets of criteria,
the PedACR and the ASAS criteria.
Adalimumab was well tolerated in this study. Only one
patient terminated the treatment prematurely, (partly)
due to adverse events (disease flare with trochanter
Figure 4 ASAS40. Percentage of patients who achieved an ASAS40. P-value of adalimumab treated patients versus placebo is outlined based on
an intention-to-treat analysis (c2-test). One patient in each group discontinued prematurely before week 4. The data were included in a last
observation carried forward modus. At week 12, all patients remaining patients switched to open label adalimumab.




Sequence Adalimumab-Adalimumab Sequence Placebo- Adalimumab
Pain2,4 Colitis3,4
Vertigo3,4 Pyelonephritis1,4
1Judged as possibly related; 2Judged as not related; 3Judged as probably not
related; 4Outcome: recovered completely. There were no events of
malignancy, demyelinating disorders or deaths.
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enthesitis on both sides). Serious adverse events were
observed in seven patients. In two patients the respective
events (appendicitis, pyelonephritis) were possibly related
to adalimumab. Clinical significant laboratory abnormal-
ities related to adalimumab were not detected.
In the majority of randomized controlled trials in child-
hood rheumatic diseases, withdrawal study designs were
used, but there remain questions of efficacy as well as
of safety. Therefore, for the present study, a primary pla-
cebo-controlled design was chosen. Here, patients treated
with adalimumab showed a continuous improvement with
an increasing intensity with ongoing treatment. The
strength of improvement also increased during the open
label period from week 12 to week 24. Superiority over
those patients treated with placebo was especially evident
at week 4 and week 8. These differences were statistically
significant although the total patient number included in
the study was small. However, at week 12 the manifesta-
tions in some of the placebo patients improved, resulting
in a loss of significance of the inter-group differences. In
these patients improvement may be due to an effect of
concomitant treatment with non-steroidal anti-inflamma-
tory drugs, although their dosage was stable before the
patients participated to the study, or was explained by a
spontaneous remitting course. This effect, however, also
may be in part responsible for the increasing improvement
in all patients with prolonged treatment.
Except for non-steroidal anti-inflammatory drugs,
so far there is no established alternative treatment option
for patients with axial JoAS. Sulfasalazine showed some
efficacy in treatment of JIA, especially in HLA B27-asso-
ciated arthritis [37]. In a clinical trial on polyarticular
JIA, the effect on joint tenderness, joint swelling, joint
score and laboratory parameters was only marginally sig-
nificant [38]. In patients with juvenile spondyloarthritis, a
placebo-controlled double-blind study demonstrated an
advantage of sulfasalazine over placebo in peripheral
joint involvement [39]. There is no study on sulfasalazine
in juvenile patients who have been classified as ankylos-
ing spondylitis, but according to studies in adult AS,
sulfasalazine probably has no effect on axial involvement
[40,41].
For this study, modified NY criteria by requiring MRI
rather than radiography was used due to (1) ethical issues
involved with radiation and (2) newer concepts of classi-
fication in which MRI is sufficient for diagnosis of axial
spondyloarthritis. In this study none of the 34 patients
with radiographic sacrioiliitis had current back pain [42].
TNF-antagonists open new perspectives for treatment
of juvenile spondylarthritis and, especially, juvenile anky-
losing spondylitis since they have effected dramatic
improvements also in patients with severe, and so far
intractable, disease. Furthermore, the velocity and the
strength of its effects on clinical activity are remarkable.
With this double-blind controlled trial we offer data on
the efficacy and, although experienced on a limited num-
ber of patients, on safety of adalimumab in children with
juvenile ankylosing spondylitis.
Limitations
Shortcomings of the study are the low number of patients
attributed to the rarity of the disease and the differences
between both the adalimumab patient group and the pla-
cebo patient group at baseline, despite randomization.
Furthermore, it would have been interesting to have MRI
data at week 12 and 24 in the patients; perhaps we would
have seen more differences between the groups.
Conclusions
This study, performed in compliance with ICH Good
Clinical Practice, showed a significant superiority of ada-
limumab compared with placebo in the treatment of
juvenile ankylosing spondylitis. The superior efficacy was
especially based on numerical rating scales, laboratory
measures of inflammation and questionnaires for func-
tional disorders. Adalimumab was well tolerated and
highly effective in the treatment of juvenile ankylosing
spondylitis in children and adolescents aged 12 to
<18 years and should be considered in the treatment of
JoAS that is active and refractory to NSAID.
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